Metabolic Dysfunction-Associated Steatohepatitis

Disease State Hub

Pearls of Wisdom

Research Summaries

Research Summary

Research Summary

Efruxifermin Demonstrates Significant Fibrosis Improvement in Patient with MASH Over 96 Weeks

09/16/2025

Kate Young

In a phase 2b trial, efruxifermin significantly improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis, with the 50 mg dose showing the greatest benefit.

09/16/2025

FDA Alert

FDA Approves Injection Therapy for Metabolic-Associated Steatohepatitis in Adults with Moderate to Advanced Fibrosis

08/25/2025

Kate Young

The FDA has announced the approval of the semaglutide injection to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis following promising interim analysis data. ...

08/25/2025

FDA Alert

FDA Alert

FDA Approves First Treatment for Adults With MASH, Serious Liver Disease

03/21/2024

Anthony Calabro, MA

The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.

03/21/2024

Research Summary

Guideline Update from the American Diabetes Association for the Detection, Management of Patients With Diabetes, Nonalcoholic Fatty Liver Disease

06/28/2023

Based on recent scientific knowledge, the American Diabetes Association (ADA) released a set of updates including recommendations for the detection and management of nonalcoholic fatty liver disease in...

06/28/2023

Treatment

Treatment Options for Patients With NAFLD, NASH

12/08/2020

Identifying treatment options for patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis was among the key topics at the American Association for the Study of Liver Diseases session...

12/08/2020

April 2026

Current Issue

April 2026